| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014324 |
| Receipt No. | R000016675 |
| Official scientific title of the study | A randomized controlled trial for improving knee joint pain in human |
| Date of disclosure of the study information | 2014/06/20 |
| Last modified on | 2017/01/30 (Ver. 11) |
| Basic information | ||
| Official scientific title of the study | A randomized controlled trial for improving knee joint pain in human | |
| Title of the study (Brief title) | A randomized controlled trial for improving knee joint pain in human | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effect of Boswellin Super or NiLitis on knee joint pain in human. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Questionnaires (JKOM) |
| Key secondary outcomes | Serum Hyarulonic acid
Serum hs-CRP Questionnaires (Likert scale) Questionnaires (WOMAC) Blood test Urianalysis Physical examinations |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 8 weeks
Test material: Boswellin Super 300 mg One tablet per day (300 mg/day) |
|
| Interventions/Control_2 | Duration: 8 weeks
Test material: 449 mg One tablet per day (449 mg/day) |
|
| Interventions/Control_3 | Duration: 8 weeks
Test material: 449 mg Two tablets per day (898 mg/day) |
|
| Interventions/Control_4 | Duration: 8 weeks
Test material: placebo 300 mg One tablet per day (300 ml/day) |
|
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | a) Healthy adults, who have knee joint pain
b) Persons who are 60s, 50s, 40s, 30s and 20s |
|||
| Key exclusion criteria | a) Persons who have previous medical history of malignant tumor, or heart failure and/or myocardial infarction
b) Patients being treated for at least one of following diseases atrial fibrillation, cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, and/or other chronic disease c) Persons who take medicines, herbal medicines, or dietary supplements d) Persons who are allergic to medicines, or foods related to the test material of this trial e) Pregnant women, lactating women, or women who want to get pregnant during the trial period f) Persons who have been enrolled in the other clinical trials within last 3 months before the agreement for the participation to this trial g) Persons who are judged not suitable to participate in this trial by physician. |
|||
| Target sample size | 96 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuo YAMAMOTO |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| kazu@orthomedico.jp | |
| Public contact | |
| Name of contact person | Naoko SUZUKI |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| Homepage URL | |
| nao@orthomedico.jp | |
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Sabinsa Japan Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Seishin-kai Medical Association Inc, Takara Medical Clinic. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団 盛心会 タカラクリニック (東京都)
Seishin-kai Medical Association Inc, Takara Medical Clinic (Tokyo) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016675 |